Catherine Lee1, Devon K Check2, Leslie Manace Brenman3, Lawrence H Kushi4, Mara M Epstein5, Christine Neslund-Dudas6, Pamala A Pawloski7, Ninah Achacoso4, Cecile Laurent4, Louis Fehrenbacher8, Laurel A Habel4. 1. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. catherine.lee@kp.org. 2. Department of Population Health Sciences, Duke University School of Medicine, Duke Cancer Institute, Durham, NC, USA. 3. Kaiser Permanente Northern California Breast Cancer Tracking System, Oakland, CA, USA. 4. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 5. Meyers Primary Care Institute and the Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA. 6. Department of Public Health Sciences, Henry Ford Health System and the Henry Ford Cancer Institute, Detroit, MI, USA. 7. HealthPartners Institute, Minneapolis, MN, USA. 8. Kaiser Permanente Northern California Medical Oncology, Oakland, CA, USA.
Abstract
PURPOSE: Reports suggest that up to 50% of women with hormone receptor-positive (HR+) breast cancer (BC) do not complete the recommended 5 years of adjuvant endocrine therapy (AET). We examined the impact of an outreach program at Kaiser Permanente Northern California (KPNC) on adherence and discontinuation of AET among patients who initiated AET. METHODS: We assembled a retrospective cohort of all KPNC patients diagnosed with HR+, stage I-III BC initiating AET before (n = 4287) and after (n = 3580) implementation of the outreach program. We compared adherence proportions and discontinuation rates before and after program implementation, both crude and adjusted for age, race/ethnicity, education, income, and stage. We conducted a pooled analysis of data from six Cancer Research Network (CRN) sites that had not implemented programs for improving AET adherence, using identical methods and time periods, to assess possible secular trends. RESULTS: In the pre-outreach period, estimated adherence in years 1, 2, and 3 following AET initiation was 75.2%, 71.0%, and 67.3%; following the outreach program, the estimates were 79.4%, 75.6%, and 72.2% (p-values < .0001 for pairwise comparisons). Results were comparable after adjusting for clinical and demographic factors. The estimated cumulative incidence of discontinuation was 0.22 (0.21-0.24) and 0.18 (0.17-0.19) at 3 years for pre- and post-outreach groups (p-value < .0001). We found no evidence of an increase in adherence between the study periods at the CRN sites with no AET adherence program. CONCLUSION: Adherence and discontinuation after AET initiation improved modestly following implementation of the outreach program.
PURPOSE: Reports suggest that up to 50% of women with hormone receptor-positive (HR+) breast cancer (BC) do not complete the recommended 5 years of adjuvant endocrine therapy (AET). We examined the impact of an outreach program at Kaiser Permanente Northern California (KPNC) on adherence and discontinuation of AET among patients who initiated AET. METHODS: We assembled a retrospective cohort of all KPNC patients diagnosed with HR+, stage I-III BC initiating AET before (n = 4287) and after (n = 3580) implementation of the outreach program. We compared adherence proportions and discontinuation rates before and after program implementation, both crude and adjusted for age, race/ethnicity, education, income, and stage. We conducted a pooled analysis of data from six Cancer Research Network (CRN) sites that had not implemented programs for improving AET adherence, using identical methods and time periods, to assess possible secular trends. RESULTS: In the pre-outreach period, estimated adherence in years 1, 2, and 3 following AET initiation was 75.2%, 71.0%, and 67.3%; following the outreach program, the estimates were 79.4%, 75.6%, and 72.2% (p-values < .0001 for pairwise comparisons). Results were comparable after adjusting for clinical and demographic factors. The estimated cumulative incidence of discontinuation was 0.22 (0.21-0.24) and 0.18 (0.17-0.19) at 3 years for pre- and post-outreach groups (p-value < .0001). We found no evidence of an increase in adherence between the study periods at the CRN sites with no AET adherence program. CONCLUSION: Adherence and discontinuation after AET initiation improved modestly following implementation of the outreach program.
Entities:
Keywords:
Adherence; Adjuvant endocrine therapy; Breast cancer; Discontinuation; Intervention; Outreach
Authors: Jessica Chubak; Rebecca Ziebell; Robert T Greenlee; Stacey Honda; Mark C Hornbrook; Mara Epstein; Larissa Nekhlyudov; Pamala A Pawloski; Debra P Ritzwoller; Nirupa R Ghai; Heather Spencer Feigelson; Heather A Clancy; V Paul Doria-Rose; Lawrence H Kushi Journal: Cancer Causes Control Date: 2016-09-17 Impact factor: 2.506
Authors: Harold J Burstein; Sarah Temin; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Diana Rowden; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2014-05-27 Impact factor: 44.544
Authors: Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach Journal: Breast Cancer Res Treat Date: 2022-03-11 Impact factor: 4.872